Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

The Lancet Oncology

Volumn 10, Issue 6, 2009, Pages 581-588

  Kaufman, Bella ^a   Trudeau, Maureen ^b   Awada, Ahmad ^c   Blackwell, Kimberly ^d   Bachelot, Thomas ^e   Salazar, Vanessa ^f   DeSilvio, Michelle ^f   Westlund, Ronald ^f   Zaks, Tal ^f   Spector, Neil ^d   Johnston, Stephen ^g  

^a SHEBA MEDICAL CENTER   (Israel)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c JULES BORDET INSTITUTE   (Belgium)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CENTRE LÉON BÉRARD   (France)

^f GLAXOSMITHKLINE   (United States)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE HEPATITIS; ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; BACKACHE; BREAST BIOPSY; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DUODENUM OBSTRUCTION; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; JAUNDICE; LUNG EDEMA; MAJOR CLINICAL STUDY; MASTITIS; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEPSIS; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; RECURRENCE; SKIN DISEASES; TREATMENT OUTCOME;

EID: 66149093901     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70087-7     Document Type: Article

References (34)

1. Liauw S.L., Benda R.K., Morris C.G., and Mendenhall N.P. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer 100 (2004) 920-928
2. Boussen H., Bouzaiene H., Ben Hassouna J., Gamoudi A., Benna F., and Rahal K. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35 (2008) 17-24
3. Cristofanilli M., Buzdar A.U., and Hortobagyi G.N. Update on the management of inflammatory breast cancer. Oncologist 8 (2003) 141-148
4. Giordano S.H., and Hortobagyi G.N. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 5 (2003) 284-288
5. Jaiyesimi I.A., Buzdar A.U., and Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 10 (1992) 1014-1024
6. Piera J.M., Alonso M.C., Ojeda M.B., and Biete A. Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol 7 (1986) 199-204
7. Charafe-Jauffret E., Tarpin C., Bardou V.J., et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202 (2004) 265-273
8. Leebours F., Bieche I., and Lidereau R. Review: update on inflammatory breast cancer. Breast Cancer Rev 7 (2005) 52-58
9. Kaptain S., Tan L.K., and Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 10 (2001) 139-152
10. Klijn J.G., Berns P.M., Schmitz P.I., and Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13 (1992) 3-17
11. Kleer C.G., van Golen K.L., and Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2 (2000) 423-429
12. Chang S., Parker S.L., Pham T., Buzdar A.U., and Hursting S.D. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
13. Low J.A., Berman A.W., Steinberg S.M., Danforth D.N., Lippman M.E., and Swain S.M. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22 (2004) 4067-4074
14. Buzdar A.U., Singletary S.E., Booser D.J., Frye D.K., Wasaff B., and Hortobagyi G.N. Combined modality treatment of stage III and inflammatory breast cancer: M D Anderson Cancer Center experience. Surg Oncol Clin N Am 4 (1995) 715-734
15. Palangie T., Mosseri V., Mihura J., et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A (1994) 921-927
16. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1 (2001) 85-94
17. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 (2002) 6255-6263
18. Johnston S., Trudeau M., Kaufman B., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26 (2008) 1066-1072
19. Dawood S., and Cristofanilli M. What progress have we made in managing inflammatory breast cancer?. Oncology 21 (2007) 673-679
20. Anderson W.F., Schairer C., Chen B.E., Hance K.W., and Levine P.H. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22 (2005) 9-23
21. Dawood N., Ueno T., and Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol 35 (2008) 64-71
22. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at 31st Annual San Antonio Breast Cancer Symposium; Dec 10-14, 2008; San Antonio, TX (abstr 31).
23. Baselga J., Semiglazov V., Manikhas G.M., et al. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (Neoadjuvant Herceptin) phase III trial. Eur J Cancer Suppl 5 (2007) (abstr 2030).
24. Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Presented at 29th Annual San Antonio Breast Cancer Symposium; Dec 14-17, 2006; San Antonio, TX (abstr 1).
25. Harris E.E., Schultz D., Bertsch H., Fox K., Glick J., and Solin L.J. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 55 (2003) 1200-1208
26. Burstein H.J., Storniolo A.M., Franco S., et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19 (2008) 1068-1074
27. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
28. Xia W., Husain I., Liu L., et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67 (2007) 1170-1175
29. van Golen K.L., Davies S., Wu Z.F., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5 (1999) 2511-2519
30. Smith B.L., Chin D., Maltzman W., Crosby K., Hortobagyi G.N., and Bacus S.S. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 91 (2004) 1190-1194
31. Lu Y., Zi X., Zhao Y., Mascarenhas D., and Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93 (2001) 1852-1857
32. Nahta R., Yuan L.X., Du Y., and Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6 (2007) 667-674
33. Crown J.P., Burris III H.A., Boyle F., et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112 (2008) 317-325
34. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 22 (2006) 28-34